Research and Markets has announced the addition of the "Tyrosine Protein Kinase Lyn (Lck/Yes Related Novel Protein Tyrosine Kinase or V Yes 1 Yamaguchi Sarcoma Viral Related Oncogene Homolog or p53Lyn or p56Lyn or LYN or EC 220.127.116.11) - Pipeline Review, H2 2016" report to their offering.
This report provides comprehensive information on the therapeutic development for Tyrosine Protein Kinase Lyn, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tyrosine Protein Kinase Lyn and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/rfl66d/tyrosine_protein
View source version on businesswire.com: http://www.businesswire.com/news/home/20160831005780/en/Business Wire
Last updated on: 31/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.